Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

D_CANCERTYPE - Cancer diagnosis (phv00508334.v1.p1)
D_CANCERTYPE - Site of primary tumor (phv00508343.v1.p1)
D_DIFFGRADE - Tumor differentiation (phv00508345.v1.p1)
D_HISTOLOGY - Cancer histology type (phv00508335.v1.p1)
D_HISTOLOGY - Cell or tissue type or subtype of sample (phv00508344.v1.p1)
D_STAGEDX - Disease stage at diagnosis (phv00508336.v1.p1)
D_STUDYTX - Treatment received on the study (phv00508337.v1.p1)
OS - Overall survival in days (phv00508340.v1.p1)
OS_cens - Overall survival censoring (0 = No, 1 = Yes) (phv00508341.v1.p1)
PFS - Progression free survival in days (phv00508338.v1.p1)
PFS_cens - Progression free survival censoring (0 = No, 1 = Yes) (phv00508339.v1.p1)

ANALYTE_TYPE - Analyte Type (phv00508348.v1.p1)
CONSENT - Consent group as determined by DAC (phv00508326.v1.p1)
IS_TUMOR - Tumor status (phv00508347.v1.p1)
SAMPLE_ID - Sample ID (phv00508342.v1.p1)
SAMPLE_ID - Sample ID (phv00508329.v1.p1)
SUBJECT_ID - Subject ID (phv00508330.v1.p1)
SUBJECT_ID - Subject ID (phv00508325.v1.p1)
SUBJECT_ID - Subject ID (phv00508328.v1.p1)